Quiet on the insider front: nobody at Talis Biomedical Corp bought or sold TLIS shares in open-market trades this past year.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Leonard Braden Michael | 10% Owner | Buy | 25,000 | $1.48 | $37K | SEC |
| Sep 9, 2024 | Leonard Braden Michael | 10% Owner | Buy | 5,100 | $1.40 | $7K | SEC |
| Sep 5, 2024 | Leonard Braden Michael | 10% Owner | Buy | 500 | $4.00 | $2K | SEC |
| Sep 4, 2024 | Leonard Braden Michael | 10% Owner | Buy | 151 | $4.25 | $642 | SEC |
| Aug 28, 2024 | Leonard Braden Michael | 10% Owner | Buy | 1,215 | $3.96 | $5K | SEC |
| Aug 28, 2024 | Leonard Braden Michael | 10% Owner | Buy | 13,167 | $3.90 | $51K | SEC |
There were no open-market insider trades in TLIS in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in TLIS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).